Kyverna Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
KYTX$5.08-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $34,647 | $37,735 |
| Available-for-sale marketable securities | 22,896 | 13,587 |
| Prepaid expenses and other current assets | 3,121 | 1,929 |
| Total current assets | 60,664 | 53,251 |
| Restricted cash | 565 | 554 |
| Property and equipment, net | 2,326 | 2,575 |
| Operating lease right-of-use assets | 6,494 | 8,214 |
| Finance lease right-of-use assets | 1,790 | 1,652 |
| Other non-current assets | 3,356 | 678 |
| Total assets | $75,195 | $66,924 |
| Liabilities, redeemable convertible preferred stock and stockholders’ deficit | ||
| Current liabilities | ||
| Accounts payable | $4,358 | $1,451 |
| Accrued compensation | 2,812 | 1,411 |
| Accrued license expense – related party | 6,250 | 6,250 |
| Other current liabilities | 3,519 | 565 |
| Operating lease liabilities, short-term portion | 1,964 | 1,672 |
| Finance lease liabilities, short-term portion | 956 | 605 |
| Total current liabilities | 19,859 | 11,954 |
| Operating lease liabilities, net of short-term portion | 5,238 | 7,209 |
| Finance lease liabilities, net of short-term portion | 921 | 1,078 |
| Other long-term liabilities | — | 6 |
| Total liabilities | 26,018 | 20,247 |
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible preferred stock, $0.00001 par value, 114,556,997 and 97,462,067 shares authorized as of December 31, 2023 and 2022, respectively; 114,556,997 and 82,504,003 shares issued and outstanding as of December 31, 2023 and 2022, respectively; liquidation preference of $181,273 and $121,273 as of December 31, 2023 and 2022, respectively. | 180,574 | 120,674 |
| Stockholders’ deficit | ||
| Common stock, $0.00001 par value; 140,492,016 and 117,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 1,250,103 and 1,007,537 shares issued and outstanding as of December 31, 2023 and 2022, respectively; 8,125 and 454,950 shares subject to repurchase as of December 31, 2023 and 2022, respectively. | — | — |
| Additional paid-in capital | 4,642 | 1,706 |
| Accumulated other comprehensive income (loss) | 4 | (26) |
| Accumulated deficit | (136,043) | (75,677) |
| Total stockholders’ deficit | (131,397) | (73,997) |
| Total liabilities, redeemable convertible preferred stock and stockholders’ deficit | $75,195 | $66,924 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.